Chief Technical Officer · Allogene Therapeutics, Inc. (ALLO)

Alison Moore

A named executive officer of Allogene Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$5,279,236

Salary $490,000Stock awards $0

FY2021: $3,547,012

3rd of 5 named executive officers at Allogene Therapeutics by FY2022 total.

5 named officers on file for Allogene Therapeutics, FY2022

Alison Moore’s pay file — $29

  • 5 fiscal years of pay, line by line
  • 7 equity grants, each cited to its filing
  • ALLO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Allogene Therapeutics’s whole pay program stands against its peers

  • Allogene Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ALLO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2023 (DEF 14A).

Free

Get Alison Moore’s full pay file as a PDF — free

More than this page: up to 10 years of Alison’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Alison Moore compensation by year

Allogene Therapeutics Summary Compensation Table · all 5 fiscal years held
In US dollars, as Allogene Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022
Salary$233,265$425,000$440,000$475,000$490,000
Bonus$0$0$0$75,000$0
Stock awards$0$996,275$561,176$839,973$0
Option awards$1,401,225$1,519,700$1,262,643$1,963,489$4,599,111
Non-equity incentive$102,124$187,000$220,000$180,500$176,400
Pension and deferred compensation$0$0$0$0$0
All other$100,000$0$0$13,050$13,725
Total$1,836,614$3,127,975$2,483,819$3,547,012$5,279,236

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Allogene Therapeutics, Inc. DEF 14A filed April 24, 2023, accession 0001737287-23-000041, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Allogene Therapeutics, Inc. filed document, accession 0001737287-23-000041. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2023.

$1.8M
$3.1M
$2.5M
$3.5M
$5.3M
FY18
FY19
FY20
FY21
FY22
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU18,650$117,309—
RSU15,400$96,866—
RSU9,263$58,264—

Per the Outstanding Equity Awards at Fiscal Year-End table in Allogene Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Allogene Therapeutics’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
David ChangPresident and Chief Executive Officer$14,797,837
Eric SchmidtChief Financial Officer$5,279,677
Alison Moore · this pageChief Technical Officer$5,279,236
Rafael AmadoFormer Executive Vice President of Research and Development$5,244,710
Veer BhavnagriFormer General Counsel$4,066,186

The full Allogene Therapeutics compensation record

free company brief

This page is one person within Allogene Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Allogene Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Allogene Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Alison Moore's compensation dossier · One-time report. No refunds.